Patient characteristics
| No. . | Age, y . | Sex . | Clinical stage . | PS . | LDH, >WLN . | IPI risk . | Presence of B symptom . | COO . | IHC . | cfDNA, ng/p-mL . | Prognosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD5 . | CD10 . | BCL6 . | MUM1 . | PD-L1 . | PD-L2 . | PFS, mo . | OS, mo . | Outcome . | ||||||||||||
| 28-8 . | E1J2J . | SP142 . | ||||||||||||||||||
| IVL_01 | 76 | F | IV | 4 | Y | H | + | Non-GCB | + | − | − | + | + | + | − | − | 1109.5 | 6 | 7 | DOD |
| IVL_02 | 80 | M | IV | 1 | Y | H | + | Non-GCB | − | − | + | + | + | + | + | − | 286.6 | 77 | 77 | AND |
| IVL_03 | 66 | M | IV | 1 | Y | H | + | Non-GCB | − | − | − | + | − | − | − | − | 1058.7 | 70 | 70 | AND |
| IVL_04 | 81 | M | IV | 1 | Y | H | + | Non-GCB | − | − | − | + | − | − | − | − | 631.9 | 68 | 68 | AND |
| IVL_05 | 61 | F | IV | 3 | Y | H | − | Non-GCB | − | − | + | + | − | − | − | + | 70.4 | 66 | 66 | AND |
| IVL_06 | 59 | M | IV | 2 | Y | H | − | Non-GCB | + | − | −/+ | + | n/a | n/a | n/a | n/a | n/a | 8 | 57 | AWD |
| IVL_07 | 72 | M | IV | 2 | Y | H | + | Non-GCB | + | − | − | + | + | + | − | − | n/a | 1 | 1 | DOD |
| IVL_08 | 77 | M | IV | 2 | Y | H | + | Non-GCB | − | − | + | + | − | − | − | − | n/a | 62 | 62 | DOO |
| IVL_09 | 59 | F | IV | 0 | Y | H-I | + | Non-GCB | + | − | +/− | + | + | n/a | + | − | 619.7 | 43 | 43 | AND |
| IVL_10 | 78 | F | IV | 1 | N | H-I | − | Non-GCB | − | − | − | + | + | n/a | − | − | 37.0 | 21 | 22 | DOD |
| IVL_11 | 66 | M | IV | 2 | Y | H | + | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 631.5 | 48 | 48 | AND |
| IVL_12 | 77 | M | IV | 2 | Y | H | + | Non-GCB | + | − | + | + | + | + | + | − | 321.5 | 12 | 25 | DOD |
| IVL_13 | 84 | F | IV | 3 | Y | H | + | Non-GCB | n/a | − | + | + | − | − | − | − | 130.9 | 1 | 1 | DOD |
| IVL_14 | 68 | F | IV | 3 | Y | H | + | Non-GCB | n/a | − | − | + | + | + | − | − | 290.5 | 35 | 35 | AND |
| IVL_15 | 47 | M | IV | 2 | Y | H | + | n/a | n/a | n/a | n/a | n/a | + | n/a | − | − | 451.3 | 27 | 27 | AND |
| IVL_16 | 68 | M | IV | 1 | Y | H-I | + | Non-GCB | n/a | − | − | + | − | − | − | − | 353.3 | 47 | 47 | AND |
| IVL_18 | 80 | M | IV | 1 | Y | H | + | Non-GCB | n/a | − | − | − | − | − | − | − | 476.4 | 49 | 49 | AND |
| IVL_19 | 54 | M | IV | 1 | Y | H-I | + | Non-GCB | + | − | − | + | + | + | − | − | 111.0 | 66 | 66 | AND |
| IVL_20 | 62 | M | IV | 2 | Y | H | + | Non-GCB | + | − | − | + | + | n/a | − | − | 624.9 | 25 | 25 | AND |
| IVL_21 | 75 | F | IV | 2 | Y | H | + | Non-GCB | n/a | − | − | + | + | n/a | − | − | 57.7 | 31 | 31 | AND |
| IVL_22 | 71 | F | IV | 2 | Y | H | + | GCB | + | + | − | + | + | + or +/− | − | − | 3679.9 | 36 | 36 | AND |
| No. . | Age, y . | Sex . | Clinical stage . | PS . | LDH, >WLN . | IPI risk . | Presence of B symptom . | COO . | IHC . | cfDNA, ng/p-mL . | Prognosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD5 . | CD10 . | BCL6 . | MUM1 . | PD-L1 . | PD-L2 . | PFS, mo . | OS, mo . | Outcome . | ||||||||||||
| 28-8 . | E1J2J . | SP142 . | ||||||||||||||||||
| IVL_01 | 76 | F | IV | 4 | Y | H | + | Non-GCB | + | − | − | + | + | + | − | − | 1109.5 | 6 | 7 | DOD |
| IVL_02 | 80 | M | IV | 1 | Y | H | + | Non-GCB | − | − | + | + | + | + | + | − | 286.6 | 77 | 77 | AND |
| IVL_03 | 66 | M | IV | 1 | Y | H | + | Non-GCB | − | − | − | + | − | − | − | − | 1058.7 | 70 | 70 | AND |
| IVL_04 | 81 | M | IV | 1 | Y | H | + | Non-GCB | − | − | − | + | − | − | − | − | 631.9 | 68 | 68 | AND |
| IVL_05 | 61 | F | IV | 3 | Y | H | − | Non-GCB | − | − | + | + | − | − | − | + | 70.4 | 66 | 66 | AND |
| IVL_06 | 59 | M | IV | 2 | Y | H | − | Non-GCB | + | − | −/+ | + | n/a | n/a | n/a | n/a | n/a | 8 | 57 | AWD |
| IVL_07 | 72 | M | IV | 2 | Y | H | + | Non-GCB | + | − | − | + | + | + | − | − | n/a | 1 | 1 | DOD |
| IVL_08 | 77 | M | IV | 2 | Y | H | + | Non-GCB | − | − | + | + | − | − | − | − | n/a | 62 | 62 | DOO |
| IVL_09 | 59 | F | IV | 0 | Y | H-I | + | Non-GCB | + | − | +/− | + | + | n/a | + | − | 619.7 | 43 | 43 | AND |
| IVL_10 | 78 | F | IV | 1 | N | H-I | − | Non-GCB | − | − | − | + | + | n/a | − | − | 37.0 | 21 | 22 | DOD |
| IVL_11 | 66 | M | IV | 2 | Y | H | + | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 631.5 | 48 | 48 | AND |
| IVL_12 | 77 | M | IV | 2 | Y | H | + | Non-GCB | + | − | + | + | + | + | + | − | 321.5 | 12 | 25 | DOD |
| IVL_13 | 84 | F | IV | 3 | Y | H | + | Non-GCB | n/a | − | + | + | − | − | − | − | 130.9 | 1 | 1 | DOD |
| IVL_14 | 68 | F | IV | 3 | Y | H | + | Non-GCB | n/a | − | − | + | + | + | − | − | 290.5 | 35 | 35 | AND |
| IVL_15 | 47 | M | IV | 2 | Y | H | + | n/a | n/a | n/a | n/a | n/a | + | n/a | − | − | 451.3 | 27 | 27 | AND |
| IVL_16 | 68 | M | IV | 1 | Y | H-I | + | Non-GCB | n/a | − | − | + | − | − | − | − | 353.3 | 47 | 47 | AND |
| IVL_18 | 80 | M | IV | 1 | Y | H | + | Non-GCB | n/a | − | − | − | − | − | − | − | 476.4 | 49 | 49 | AND |
| IVL_19 | 54 | M | IV | 1 | Y | H-I | + | Non-GCB | + | − | − | + | + | + | − | − | 111.0 | 66 | 66 | AND |
| IVL_20 | 62 | M | IV | 2 | Y | H | + | Non-GCB | + | − | − | + | + | n/a | − | − | 624.9 | 25 | 25 | AND |
| IVL_21 | 75 | F | IV | 2 | Y | H | + | Non-GCB | n/a | − | − | + | + | n/a | − | − | 57.7 | 31 | 31 | AND |
| IVL_22 | 71 | F | IV | 2 | Y | H | + | GCB | + | + | − | + | + | + or +/− | − | − | 3679.9 | 36 | 36 | AND |
AND, alive with no evidence of disease; AWD, alive with disease; COO, cell of origin; CRP, C-reactive protein; DOD, dead of disease; DOO, dead of other diseases; GCB, germinal center B-cell type; H, high; H-I, high-intermediate; IHC, immunohistochemistry; IVL, intravascular large B-cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; n/a, not available; ng/p-mL, nanogram per 1 mL of plasma; non-GCB, non germinal center B-cell type; PS, performance status; UPN, unique patient number; WBC, white blood cell count; WLN, within limit of normal; Y, yes.